I have to say, I’m a bit dissapointed looking at their stock performance in the last 3 months. The price has been declining from $0.45/share to $0.28/share. I have no idea what’s going on with them…

Looking back to what they’ve accomplished in the past 12 months:
First, they got funding from the California state department.
Second, they got another funding from a private, global investment bank…And many other things that I’m not going to mention one by one here.
Third, If you look at the industry, this company is already in the right industry to begin with. They’re in fuel cell industry, which obviously is going to be the most-money-making industry in the next decade.

So what made the price decrease a lot in the past 3 months? Hmm…This is definitely a million dollar question.

I found this article when I was doing research on fuel cell. Here’s the link: http://www.evworld.com/view.cfm?section=communique&newsid=7462. The article is pretty interesting. It talks about how big auto companies, like Toyota and GM, are currently doing in terms of fuel cell technology, how GM increased its funding and has reportedly poured more than US$1 billion into fuel cell R&D programs since 2000, etc…

I’ve always believed fuel cell is going to be big in the next 10 years, that’s why I’ve been holding on to this stock for the last 3 years. I could’ve sold them a year ago and made a couple of grand. But hey, I decided to wait - it’s not because I’m greedy - it’s because I knew it wasn’t the right time to sell them. I’m just going to wait until the price has literally gone through the roof…And that’s payday, my friend!

Quote of the Day:
Debt is the worst poverty. - Thomas Fuller

I wrote about this company a while ago. Recently they had a press release about them announcing the first delivery of Actinium-225, a rare but promising cancer-fighting radio-isotope to the National Cancer Institute, a part of the National Institutes of Health (NIH), the federal government’s leading medical research organization. I have to tell you, the more I know about this company, the more I become more interested in investing in it. Of course, I’ve said so many times to myself that I would never invest in anything that’s traded at more than $1/share. But this one…Mmm looks like it becomes more and more appealing.

Here’s their price/share chart (starting from February 2004 - January 2005)

I know the price fluctuated a bit in the past 3 months, but hey it went up from under $2/share in September 2004 to $6/share in December. And I think 2005 should be a good year for them since they somehow decided to branch out to medical industry.

“…Isonics has received exclusive marketing and sales rights for all of the Actinium-225 produced by IPPE. Assuming that IPPE reaches target production levels over the next year, Isonics expects that this will nearly double the existing global supply of Actinium-225. Currently, research includes clinical trials for therapies for leukemia and lymphoma. Numerous pre-clinical results have been published demonstrating the potential application of Bismuth-213 as a therapeutic for metastatic disease, bone marrow transplant, as well as treatments of fungal and bacterial infection.
Independent medical researchers welcomed the projected Actinium supply increases. “Clinical results to date have looked very promising, but lack of availability of the isotope Actinium-225 and the present high cost for that which is available has greatly limited the research,” said Dr. Barbara Y. Croft, of the National Cancer Institute. “I am greatly encouraged that Isonics is working with IPPE to expand availability of Actinium-225, which will enable a greater number of promising research projects to proceed…”

That’s what they say in the article which was recently published in Business Wire. Very interesting, huh?

Quote of the Day:
Investors in the corporate bond market do not enjoy the same access to information as a car buyer or, dare I say, a fruit buyer. - SEC Chairman Arthur Levitt

Stumbled upon this one when I did my research last night. This company, Motion DNA (Symbol: MTDX) was founded to commercialize its innovative, diagnostic motion capture system that monitors and identifies physical characteristics for improvement of the motions of the human body. The company markets this technology to medical professionals, sports organizations, professional athletes, and even large companies looking to prevent physical strain and injury to its employees. They provide analyses and detailed reports to its licensees and consumers with solutions for preventing injuries, identifying physical limitations, diagnosing pre-existing injuries related to biomechanics, and improving physical performance levels.

Looking at their historical data, I’m little bit sceptical if this stock is going to perform well in the future. A month ago, they were traded at 0.18/share; 3 months ago they were traded as high as $0.30/share. Hell a year ago, they were traded at $1/share. Currently they’re traded at $0.01/share. There must be a good reason why the price dropped a lot within one year.

Recently there was an article about them published in Business Wire. Here it is:

“Motion DNA Corporation (OTC:MTDX) officials announced today an upcoming marketing schedule of events for 2004 and 2005. The marketing schedule kicks off with demonstrating its products and services at the upcoming Baseball Tradeshow in Anaheim, California, December 10-12, 2004. Company officials expect to expose the company’s technology to professional baseball teams of all levels at the convention. Coaches, front office executives, and medical professionals representing teams from the MLB and minor league organizations are expected to attend the tradeshow, which is held in conjunction with the Baseball Winter Meetings for professional teams. Representatives in baseball from collegiate and professional teams have expressed an increasing interest in Motion DNA’s analysis primarily for evaluating the risks of shoulder and elbow injuries in pitchers. An injury to a key player can cost a professional team millions of dollars each year. The losses add up when teams look at wages paid to the injured player, lost gate receipts, and missed post season revenues due to the injury to one player.
“Our goal is annual testing for athletes involved in sports where there is a high risk of injury to a particular group. The fee for Motion DNA’s full analysis for a pitcher ranges from $200 to $900 per player depending upon our report’s detail and could add up to over $200,000 per team,” said Zig Ziegler, President of Motion DNA.
“However, the company offers a much lower flat fee for annual contracts with a schedule consisting of 4 tests annually for pitchers only conducted at a site determined by the client.”
Company officials believe that if major league baseball requires its at-risk athletes to be tested, collegiate and high school programs are sure to follow suit, along with other sports.
“If I am the owner of a professional team spending millions of dollars on even one player … counting on them to stay healthy, this is just a small fee to help ease my mind and insure my product (which in today’s sports business world is the athlete) works properly,” added Ziegler. (http://biz.yahoo.com/bw/041128/285028_1.html November 28, 9:40 am - Yahoo Finance)

So what do you think, huh? At $0.01/share, this stock might not be a bad investment. It’s cheap, judging from the services offered - looks like they still have a good potential to become a bigger company, and it’s a low risk. Put in a hundred bucks, you’ll get 1,000 shares. When the price hits 50 cents or something, you’ll cash out $500…Not bad, huh?

Quote of the Day:
Wealth consists not in having great possessions, but in having few wants. - Epicurus

Sorry folks…I’ve been busy at work in the past few weeks. That’s why I haven’t really had a chance to sit down and do some research. Don’t worry, I’m going to post some new updates sometime this week. There are some stocks that I think are good potentials and I can’t wait to share with you guys…

Be patient, fellas…!